Publication | Closed Access

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

Post-hoc AnalysesMedicineSubsequent ChemotherapyGynecologyCancer TreatmentOncologyRadiation OncologyGynecology OncologyEndocrine-related CancerSolo2/engot Ov-21 TrialOvarian Cancer